バイオプロセスバリデーション市場：試験タイプ、プロセスコンポーネント、エンドユーザー別-2025-2030年世界予測

バイオプロセスバリデーション市場は、2023年に3億9,547万米ドルと評価され、2024年には4億5,357万米ドルに達すると予測され、CAGR 14.78%で成長し、2030年には10億3,834万米ドルに達すると予測されています。

バイオプロセスバリデーションは、バイオテクノロジーおよび製薬産業における重要な構成要素であり、生物製剤の生産に関わるプロセスが一貫して効果的であり、所定の仕様と品質属性を満たす製品を一貫して生産できることを保証することに重点を置いています。バイオプロセスバリデーションの必要性は、FDAやEMAのような機関が課す厳しい規制要件から生じ、プロセスの一貫性と製品の安全性の厳密な証拠を要求します。バイオプロセスバリデーションの主な発展は、培養、収穫から精製、製剤化まで、医薬品開発・製造の様々な段階に及び、バイオ製薬会社、受託製造機関（CMO）、研究開発機関などの主要なエンドユーザーに影響を与えています。市場の成長は、生物製剤やバイオシミラーの需要増加、バイオ医薬品の研究開発への投資、個別化医療への注目の高まりに大きく影響されています。さらに、プロセス分析技術（PAT）と自動化における技術的進歩は、バイオプロセスの効率を高め、コンプライアンスを確保するための大きな潜在的機会を提供しています。企業は、バイオプロセスのリアルタイムモニタリングと制御のための革新的なソリューションに投資したり、予測分析や品質管理システムのために人工知能や機械学習を統合したりすることで、こうした機会を活用することができます。しかし、同市場は、初期コストの高さ、プロセス設計の複雑さ、技術革新を阻害し市場投入までの時間を遅らせる厳しい規制の枠組みといった課題に直面しています。こうした課題に対処するには、費用対効果の高いバリデーション技術の進歩と、強固な標準化プロトコルの開発が必要です。技術革新のための最良の分野としては、連続製造法の探求、予測的バイオプロセスのための高度なデータ解析の導入、柔軟性を高め交差汚染リスクを低減するためのシングルユース技術の改良などが挙げられます。ダイナミックな性質と急速な技術進化を特徴とするこの市場では、競合情勢をうまく乗り切り、持続可能な成長を推進するために、継続的な適応と先見的な戦略が求められています。

市場力学：急速に進化するバイオプロセスバリデーション市場の主要市場インサイトを公開

バイオプロセスバリデーション市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 精密な安全・品質規制
  • バイオ医薬品需要の高まり
  • アウトソーシングニーズの高まりバイオプロセスバリデーション
• 市場抑制要因
  • バイオプロセスバリデーションの高コスト
• 市場機会
  • 次世代バイオ製品のための新しいバリデーション手法の開発
  • ヘルスケア分野における細胞・遺伝子治療の台頭
• 市場の課題
  • バリデーションプロセスの機能的問題

ポーターの5つの力：バイオプロセスバリデーション市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：バイオプロセスバリデーション市場における外部からの影響の把握

外部マクロ環境要因は、バイオプロセスバリデーション市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析バイオプロセスバリデーション市場における競合情勢の把握

バイオプロセスバリデーション市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスバイオプロセスバリデーション市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、バイオプロセスバリデーション市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨バイオプロセスバリデーション市場における成功への道筋を描く

バイオプロセスバリデーション市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 正確な安全性と品質規制
    • バイオ医薬品の需要増加
    • アウトソーシングのニーズの高まりバイオプロセスバリデーション
  • 抑制要因
    • バイオプロセスバリデーションのコストが高い
  • 機会
    • 次世代バイオ製品の新たな検証方法の開発
    • ヘルスケア分野における細胞・遺伝子治療の出現
  • 課題
    • 検証プロセスの機能上の問題
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 バイオプロセスバリデーション市場テストタイプ別

• 互換性テストサービス
• 抽出物または浸出物試験サービス
• 完全性試験サービス
• 微生物学的検査サービス

第7章 バイオプロセスバリデーション市場プロセスコンポーネント別

• バイオリアクター
• フィルターエレメント
• 凍結・解凍処理バッグ
• メディアコンテナとバッグ
• ミキシングシステム
• 転送システム

第8章 バイオプロセスバリデーション市場：エンドユーザー別

• バイオテクノロジー企業
• 契約開発および製造組織
• 製薬会社

第9章 南北アメリカのバイオプロセスバリデーション市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のバイオプロセスバリデーション市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのバイオプロセスバリデーション市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Almac Group
• BiOZEEN
• Eurofins Scientific SE
• Hangzhou Anow Microfiltration Co., Ltd.
• Hangzhou Cobetter Filtration Equipment Co., Ltd.
• Intertek Group PLC
• Meissner Filtration Products, Inc.
• Merck KGaA
• Nelson Laboratories, LLC by Sotera Health company
• Pall Corporation
• Porvair PLC
• Sartorius AG
• SGS S.A.
• Thermo Fisher Scientific, Inc.
• West Pharmaceutical Services, Inc.

LIST OF FIGURES

• FIGURE 1. BIOPROCESS VALIDATION MARKET RESEARCH PROCESS
• FIGURE 2. BIOPROCESS VALIDATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BIOPROCESS VALIDATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BIOPROCESS VALIDATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BIOPROCESS VALIDATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BIOPROCESS VALIDATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BIOPROCESS VALIDATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BIOPROCESS VALIDATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOPROCESS VALIDATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOPROCESS VALIDATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BIOPROCESS VALIDATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BIOPROCESS VALIDATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIOPROCESS VALIDATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BIOPROCESS VALIDATION MARKET DYNAMICS
• TABLE 7. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY COMPATIBILITY TESTING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY EXTRACTABLES OR LEACHABLES TESTING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY INTEGRITY TESTING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY MICROBIOLOGICAL TESTING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY FILTER ELEMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY FREEZING & THAWING PROCESS BAGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY MEDIA CONTAINERS & BAGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY MIXING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY TRANSFER SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BIOPROCESS VALIDATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS BIOPROCESS VALIDATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. CANADA BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CANADA BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 35. CANADA BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES BIOPROCESS VALIDATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC BIOPROCESS VALIDATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 50. CHINA BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 51. CHINA BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 52. CHINA BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. INDIA BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDIA BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 55. INDIA BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIOPROCESS VALIDATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. ITALY BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 106. ITALY BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 107. ITALY BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. POLAND BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 118. POLAND BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 119. POLAND BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 120. QATAR BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 121. QATAR BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 122. QATAR BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM BIOPROCESS VALIDATION MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM BIOPROCESS VALIDATION MARKET SIZE, BY PROCESS COMPONENT, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM BIOPROCESS VALIDATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. BIOPROCESS VALIDATION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 151. BIOPROCESS VALIDATION MARKET, FPNV POSITIONING MATRIX, 2023

The Bioprocess Validation Market was valued at USD 395.47 million in 2023, expected to reach USD 453.57 million in 2024, and is projected to grow at a CAGR of 14.78%, to USD 1,038.34 million by 2030.

Bioprocess validation encompasses a critical component in the biotechnology and pharmaceutical industries, focusing on ensuring that processes involved in the production of biologics are consistent, effective, and capable of consistently producing products meeting predetermined specifications and quality attributes. The necessity of bioprocess validation arises from the stringent regulatory requirements imposed by agencies like the FDA and EMA, demanding rigorous evidence of process consistency and product safety. Its applications span across various stages of drug development and manufacturing, from culture growth and harvest to purification and formulation, impacting key end-users such as biopharmaceutical companies, contract manufacturing organizations (CMOs), and R&D institutes. Market growth is predominantly influenced by the increasing demand for biologics and biosimilars, investments in biopharmaceutical R&D, and the growing focus on personalized medicine. Additionally, technological advancements in process analytical technologies (PAT) and automation offer significant potential opportunities for enhancing bioprocess efficiencies and ensuring compliance. Companies can capitalize on these opportunities by investing in innovative solutions for real-time monitoring and control of bioprocesses, as well as integrating artificial intelligence and machine learning for predictive analytics and quality management systems. However, the market faces challenges such as high initial costs, complexities in process design, and stringent regulatory frameworks that can stifle innovation and slow down time-to-market. Addressing these challenges requires advancements in cost-effective validation techniques and the development of robust standardized protocols. The best areas for innovation include the exploration of continuous manufacturing methods, incorporation of advanced data analytics for predictive bioprocessing, and improved single-use technologies to enhance flexibility and reduce cross-contamination risks. The market, characterized by its dynamic nature and rapid technological evolution, demands continuous adaptation and forward-thinking strategies to successfully navigate the competitive landscape and drive sustainable growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bioprocess Validation Market

The Bioprocess Validation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Precise safety and quality regulations
  • Rising demand for biopharmaceuticals
  • Growing need for outsourcing bioprocess validation
• Market Restraints
  • High cost of bioprocess validation
• Market Opportunities
  • Development of new validation methods for next-generation bioproducts
  • Emergence of cell & gene therapy in the healthcare sector
• Market Challenges
  • Functional issues with validation processes

Porter's Five Forces: A Strategic Tool for Navigating the Bioprocess Validation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bioprocess Validation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bioprocess Validation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bioprocess Validation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bioprocess Validation Market

A detailed market share analysis in the Bioprocess Validation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bioprocess Validation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bioprocess Validation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bioprocess Validation Market

A strategic analysis of the Bioprocess Validation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bioprocess Validation Market, highlighting leading vendors and their innovative profiles. These include Almac Group, BiOZEEN, Eurofins Scientific SE, Hangzhou Anow Microfiltration Co., Ltd., Hangzhou Cobetter Filtration Equipment Co., Ltd., Intertek Group PLC, Meissner Filtration Products, Inc., Merck KGaA, Nelson Laboratories, LLC by Sotera Health company, Pall Corporation, Porvair PLC, Sartorius AG, SGS S.A., Thermo Fisher Scientific, Inc., and West Pharmaceutical Services, Inc..

Market Segmentation & Coverage

This research report categorizes the Bioprocess Validation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Test Type, market is studied across Compatibility Testing Services, Extractables or Leachables Testing Services, Integrity Testing Services, and Microbiological Testing Services.
• Based on Process Component, market is studied across Bioreactors, Filter Elements, Freezing & Thawing Process Bags, Media Containers & Bags, Mixing Systems, and Transfer Systems.
• Based on End User, market is studied across Biotechnology Companies, Contract Development & Manufacturing Organizations, and Pharmaceutical Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Precise safety and quality regulations
    • 5.1.1.2. Rising demand for biopharmaceuticals
    • 5.1.1.3. Growing need for outsourcing bioprocess validation
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of bioprocess validation
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of new validation methods for next-generation bioproducts
    • 5.1.3.2. Emergence of cell & gene therapy in the healthcare sector
  • 5.1.4. Challenges
    • 5.1.4.1. Functional issues with validation processes
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Bioprocess Validation Market, by Test Type

• 6.1. Introduction
• 6.2. Compatibility Testing Services
• 6.3. Extractables or Leachables Testing Services
• 6.4. Integrity Testing Services
• 6.5. Microbiological Testing Services

7. Bioprocess Validation Market, by Process Component

• 7.1. Introduction
• 7.2. Bioreactors
• 7.3. Filter Elements
• 7.4. Freezing & Thawing Process Bags
• 7.5. Media Containers & Bags
• 7.6. Mixing Systems
• 7.7. Transfer Systems

8. Bioprocess Validation Market, by End User

• 8.1. Introduction
• 8.2. Biotechnology Companies
• 8.3. Contract Development & Manufacturing Organizations
• 8.4. Pharmaceutical Companies

9. Americas Bioprocess Validation Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Bioprocess Validation Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Bioprocess Validation Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Almac Group
• 2. BiOZEEN
• 3. Eurofins Scientific SE
• 4. Hangzhou Anow Microfiltration Co., Ltd.
• 5. Hangzhou Cobetter Filtration Equipment Co., Ltd.
• 6. Intertek Group PLC
• 7. Meissner Filtration Products, Inc.
• 8. Merck KGaA
• 9. Nelson Laboratories, LLC by Sotera Health company
• 10. Pall Corporation
• 11. Porvair PLC
• 12. Sartorius AG
• 13. SGS S.A.
• 14. Thermo Fisher Scientific, Inc.
• 15. West Pharmaceutical Services, Inc.